JAK2 and acquired polycythemia vera: The trial results showed that both PEG and HU were effective in inducing complete hematological response (CHR) at 12 months, with significant reductions in the JAK2 allelic burden observed in 58% of PV patients treated with PEG, compared to 43% with HU [149].